Sernova Corp., a clinical-stage regenerative medicine therapeutics company, focuses on the development and commercializing of its proprietary Cell Pouch System and associated technologies, including the cell pouch and systemic and/or locally immune protected therapeutic cells and tissues. More Details
Adequate balance sheet with moderate growth potential.
Share Price & News
How has Sernova's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SVA is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 35% a week.
Volatility Over Time: SVA's weekly volatility has increased from 21% to 35% over the past year.
7 Day Return
1 Year Return
Return vs Industry: SVA exceeded the Canadian Biotechs industry which returned 18% over the past year.
Return vs Market: SVA exceeded the Canadian Market which returned 2.1% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Sernova's share price compared to the market and industry in the last 5 years?
Simply Wall St News
8 months ago | Simply Wall StDoes Sernova Corp. (CVE:SVA) Have A Volatile Share Price?
9 months ago | Simply Wall StWe're Keeping An Eye On Sernova's (CVE:SVA) Cash Burn Rate
1 year ago | Simply Wall StThose Who Purchased Sernova (CVE:SVA) Shares Three Years Ago Have A 28% Loss To Show For It
Is Sernova undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate SVA's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate SVA's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: SVA is unprofitable, so we can't compare its PE Ratio to the XN Biotechs industry average.
PE vs Market: SVA is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SVA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SVA is overvalued based on its PB Ratio (216.8x) compared to the CA Biotechs industry average (6.9x).
How is Sernova forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SVA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.5%).
Earnings vs Market: SVA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: SVA's is expected to become profitable in the next 3 years.
Revenue vs Market: Insufficient data to determine if SVA's revenue is forecast to grow faster than the Canadian market.
High Growth Revenue: Insufficient data to determine if SVA's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SVA's Return on Equity is forecast to be high in 3 years time
How has Sernova performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SVA is currently unprofitable.
Growing Profit Margin: SVA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SVA is unprofitable, and losses have increased over the past 5 years at a rate of 15.5% per year.
Accelerating Growth: Unable to compare SVA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SVA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).
Return on Equity
High ROE: SVA has a negative Return on Equity (-408.01%), as it is currently unprofitable.
How is Sernova's financial position?
Financial Position Analysis
Short Term Liabilities: SVA's short term assets (CA$1.7M) exceed its short term liabilities (CA$748.4K).
Long Term Liabilities: SVA's short term assets (CA$1.7M) exceed its long term liabilities (CA$676.9K).
Debt to Equity History and Analysis
Debt Level: SVA's debt to equity ratio (45.6%) is considered high.
Reducing Debt: Insufficient data to determine if SVA's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SVA has sufficient cash runway for 3 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: SVA is forecast to have sufficient cash runway for 3 months based on free cash flow estimates, but has since raised additional capital.
What is Sernova current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SVA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SVA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SVA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SVA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SVA's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Dr. Philip M. Toleikis, B.A., M.Sc., Ph.D., has been the Chief Executive Officer and the President of Sernova Corp. since April 28, 2009. Dr. Toleikis is a seasoned and Experienced biotechnology executive,...
CEO Compensation Analysis
Compensation vs Market: Philip's total compensation ($USD628.46K) is about average for companies of similar size in the Canadian market ($USD769.99K).
Compensation vs Earnings: Philip's compensation has increased whilst the company is unprofitable.
|Independent Director||8.75yrs||CA$74.62k||0.10% |
|Independent Chairman||5.83yrs||CA$102.41k||0.15% |
|Member of Scientific Advisory Board||14.5yrs||no data||no data|
|Independent Director||12.25yrs||CA$77.12k||0.27% |
|Member of Scientific Advisory Board||14.42yrs||no data||no data|
|Member of Scientific Advisory Board||no data||no data||no data|
|Member of Scientific Advisory Board||14.08yrs||no data||no data|
|Member of Scientific Advisory Board||10.08yrs||no data||no data|
|Independent Director||1.75yrs||CA$27.06k||0.046% |
|Member of Scientific Advisory Board||2yrs||no data||no data|
|Member of Global Advisory Board||0.50yr||no data||no data|
Experienced Board: SVA's board of directors are seasoned and experienced ( 10.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.6%.
Sernova Corp.'s company bio, employee growth, exchange listings and data sources
- Name: Sernova Corp.
- Ticker: SVA
- Exchange: TSXV
- Founded: NaN
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$385.258m
- Shares outstanding: 220.15m
- Website: https://www.sernova.com
- Sernova Corp.
- The Stiller Centre
- 700 Collip Circle
- N6G 4X8
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|SVA||TSXV (TSX Venture Exchange)||Yes||Common Shares||CA||CAD||Feb 2000|
|SEOV.F||OTCPK (Pink Sheets LLC)||Yes||Common Shares||US||USD||Feb 2000|
|PSH||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Feb 2000|
Sernova Corp., a clinical-stage regenerative medicine therapeutics company, focuses on the development and commercializing of its proprietary Cell Pouch System and associated technologies, including the ce...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/01/21 23:51|
|End of Day Share Price||2021/01/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.